600+ sources. One page. See who else covered it.
A cancer biotech vying for a piece of AstraZeneca's cancer territory and a pain specialist chasing Vertex's landmark non-opioid drug are capping an IPO-heavy week. BlossomHill Therapeutics and Latigo ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Banca Monte dei Paschi di Siena exceeded profit expectations in the second quarter. Rival lender Banco BPM last week dropped a proposal to Monte Paschi to start merger discussions.
Rabobank’s Joe DeLaura details how renewed United States (US)–Iran tensions and disruptions at the Strait of Hormuz have driven a sharp rally and subsequent correction in Brent and West Texas…
Investors stood their ground ahead of a hotly anticipated jobs report and potential progress in Middle East talks.
Albar Capital Partners is to return external cash to investors and continue running its London-based market-neutral equities strategy exclusively for founder Javier Velazquez's former employer…
Chinese quantitative hedge fund managers are increasing investments in their own products, with 25 private fund firms committing more than RMB1.4bn ($195m) since the beginning of July, as managers…
US hedge fund manager DLD Asset Management is establishing a presence in Hong Kong as it seeks to expand its relative-value trading activities across Asia, hiring Maso Capital Partners co-founder…